Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
MFC Manulife Financial Corp
RTX Raytheon Technologies Corp
SEVN Seven Hills Realty Trust
$NQEG35LMGBPN Nasdaq Egypt Real Estate Large Mid C
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
MMM 3M Co
STOR STORE Capital Corp
NGG National Grid PLC
Go

Health Care : Pharmaceuticals |
Company profile

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.

Postmarket

Last Trade
Delayed
$9.67
-0.01 (-0.10%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$9.68
Day's Change
-0.34 (-3.39%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
10.46
Day's Low
9.50
Volume
(Heavy Day)
Volume:
354,337

10-day average volume:
286,563
354,337

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.